TriSalus Q2 FY26 net loss narrows 40.74% to $0.16 per share; revenue rises 1.7% to $11.4 million
TLSI•Q2 FY26 results
- TriSalus Life Sciences posted Q2 revenue of $11.4 million, up 1.7% from the prior-year period.
- Operating loss widened to $9.8 million from $7.3 million, on higher sales and marketing costs tied to commercial expansion.
- Net loss available to common stockholders was $9.2 million; loss per share narrowed to $0.16 from $0.27.
- Gross margin rose 2.9 percentage points to 86.8%, due to a lower cost per TriNav unit.
- Maintained full-year 2026 revenue guidance of $54 million to $57 million; cash and cash equivalents were $46.3 million at June 30.
